Efficacy and Safety of Neoadjuvant Immunotherapy plus Chemotherapy versus Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer Treatment: A Mixed Method Meta-Analysis Based on Global Randomized Controlled Trials

IF 10.7 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
MedComm Pub Date : 2025-05-31 DOI:10.1002/mco2.70211
Shen Li, Chenhao Xu, Yuanling Meng, Yiyang Li, Jiaqing Yang, Junxuan Du, Fan Zhang, Hu Liao, Xuelei Ma
{"title":"Efficacy and Safety of Neoadjuvant Immunotherapy plus Chemotherapy versus Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer Treatment: A Mixed Method Meta-Analysis Based on Global Randomized Controlled Trials","authors":"Shen Li,&nbsp;Chenhao Xu,&nbsp;Yuanling Meng,&nbsp;Yiyang Li,&nbsp;Jiaqing Yang,&nbsp;Junxuan Du,&nbsp;Fan Zhang,&nbsp;Hu Liao,&nbsp;Xuelei Ma","doi":"10.1002/mco2.70211","DOIUrl":null,"url":null,"abstract":"<p>This study explores the efficacy and safety of combining immunotherapy with chemotherapy for neoadjuvant non-small cell lung cancer (NSCLC) treatment. Despite the rapid advancement of immunotherapy, direct evidence comparing it with chemotherapy alone is limited. Following PRISMA guidelines, we analyzed global phase II and III randomized controlled trials data. Our meta-analysis included nine trials with 3431 participants, showing that combined treatment significantly improved event-free survival, pathological complete response, major pathological response, surgical acceptance, and R0 resection rates in NSCLC compared with chemotherapy alone. Safety analysis revealed similar all adverse event incidences between treatments, while Grade ≥3 adverse events were higher than those in neoadjuvant chemotherapy. Network meta-analysis confirmed the benefits of different immunotherapeutic drugs and efficacy in different subgroups. The study's high-quality evidence suggests that neoadjuvant immunotherapy plus chemotherapy should be considered in clinical practice for NSCLC, with further research needed to optimize treatment strategies and improve patient outcomes.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"6 6","pages":""},"PeriodicalIF":10.7000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mco2.70211","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedComm","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mco2.70211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

This study explores the efficacy and safety of combining immunotherapy with chemotherapy for neoadjuvant non-small cell lung cancer (NSCLC) treatment. Despite the rapid advancement of immunotherapy, direct evidence comparing it with chemotherapy alone is limited. Following PRISMA guidelines, we analyzed global phase II and III randomized controlled trials data. Our meta-analysis included nine trials with 3431 participants, showing that combined treatment significantly improved event-free survival, pathological complete response, major pathological response, surgical acceptance, and R0 resection rates in NSCLC compared with chemotherapy alone. Safety analysis revealed similar all adverse event incidences between treatments, while Grade ≥3 adverse events were higher than those in neoadjuvant chemotherapy. Network meta-analysis confirmed the benefits of different immunotherapeutic drugs and efficacy in different subgroups. The study's high-quality evidence suggests that neoadjuvant immunotherapy plus chemotherapy should be considered in clinical practice for NSCLC, with further research needed to optimize treatment strategies and improve patient outcomes.

新辅助免疫治疗加化疗与新辅助化疗治疗非小细胞肺癌的疗效和安全性:基于全球随机对照试验的混合方法荟萃分析
本研究探讨免疫联合化疗治疗非小细胞肺癌(NSCLC)新辅助治疗的有效性和安全性。尽管免疫疗法进展迅速,但将其与单独化疗进行比较的直接证据有限。根据PRISMA指南,我们分析了全球II期和III期随机对照试验数据。我们的荟萃分析包括9项试验,3431名参与者,显示与单独化疗相比,联合治疗显著提高了非小细胞肺癌的无事件生存期、病理完全缓解、主要病理缓解、手术接受度和R0切除率。安全性分析显示,两组不良事件发生率相似,但≥3级不良事件发生率高于新辅助化疗。网络荟萃分析证实了不同免疫治疗药物在不同亚组中的益处和疗效。该研究的高质量证据表明,在非小细胞肺癌的临床实践中应考虑新辅助免疫治疗加化疗,需要进一步研究以优化治疗策略并改善患者预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信